Nugen Medical Devices Inc · TSXV:NGMD
Nugen Medical Devices — Investor Presentation (July 2021)
18 slides from Nugen Medical Devices's investor presentation, July 2021
Slide 1: Revolutionizing Needle-Free Drug Delivery
REVOLUTIONIZING Needle-Free DRUG DELIVERY
Slide 2: Our Vision
Inolife R&D Inc. is transitioning to a new global branding as: Our Vision NuGen Medical Devices believes that every individual should have the opportunity to receive healthcare that is empowering, safe and respectful. 01
Slide 3: Disclaimer
DISCLAIMER 01 GENERAL The information provided in this presentation pertaining to NuGen Medical Devices ("NuGen MD" or "The Company"), its business assets, strategy and operations is for general informational purposes only and is not a formal offer to sell or a solicitation of an offer to buy any se
Slide 4: Global Market Opportunity $25.0B
GLOBAL MARKET OPPORTUNITY Injections are a common healthcare procedure, administered to billions every day— but the technique is increasingly going needle-free. GLOBAL VACCINATION GLOBAL NEEDLE-FREE COVERAGE¹ INJECTION SYSTEM MARKET² Current and planned All market values in USD. $25.0B CAGR $11.8B (
Slide 5: Why Needle-Free? Benefits of Needle-Free
WHY NEEDLE-FREE? BENEFITS OF NEEDLE-FREE 03 Needle-free REDUCE COSTS delivery is much 05 Patients REDUCE FEAR report less pain and cheaper than the use of needles. discomfort with needle-free Cost Per Million Injections injections, making them more Source: GEN likely to adhere to medications. Conven
Slide 6: That's Where We Come In: How It Works
THAT’S WHERE WE COME IN. HOW IT WORKS High-pressure jet injections Traditional needle syringes The company dispense micro-droplets of penetrate the skin, causing medication evenly into the skin. medication to pool over time. has perfected its needle-free devices, NEEDLE-FREE NEEDLE which are now ava
Slide 7: Timeline
TIMELINE Letter of intent Definitive Resulting to acquire EPG agreement with issuer branding maker of Insujet™ Capital Pool Company on the TSX Venture June BuzBuz Capital 2017 2020 October 2019 September Q4 Inolife Closing of R&D Canada Acquisition Engagement of of European Cannacord Genuity Pharma
Slide 8: From Concept to Commercialization
FROM CONCEPT TO COMMERCIALIZATION Platform development overview 2005 2016 2019 2020 2020 First prototypes Re-design and Prototype of electric Jet-injectors ready Prototype of of spring powered mass production powered Jet-injectors with for commercialization multiple-dose ORE NEE Jet-injectors for op
Slide 9: Key Target Markets
KEY TARGET MARKETS NuGen MD’s devices can be applied across diverse markets, from home healthcare to diabetes. IVF Services Market Human Growth Hormone Market Global Diabetes Drug Market Adults with Diabetes CAGR (2019-2026): 9.3% CAGR (2020-2027): 8.2% CAGR (2019-2026): 4.3% 2018 $12.5B 2020 $4.9B
Slide 10: Global Reach
GLOBAL REACH GLOBAL OFFICES In progress: U.S., Canada, China EUROPE AMSTERDAM TORONTO ISRAEL FILING Q4 2020 SAUDI ARABIA TAIWAN The company has achieved SHENZHEN multiple regulatory approvals HONG KONG and is cleared to sell its devices in over 40 countries. MALAYSIA BRAZIL AUSTRALIA SOUTH AFRICA NE
Slide 11: Nanoparticle Powder Injectable
NANOPARTICLE POWDER INJECTABLE DISRUPTIVE NEXT-GENERATION DEVICE In emerging countries, camels deliver vaccines in refrigerated and solar-powered containers. THERMOSTABLE IMPROVED EFFICACY CONTROLLED RELEASE New powder drug Demonstrated possible Encapsulation offers the In contrast, nanoparticle-red
Slide 12: Nanojex - Powder Vaccine Injector
NANOJEX - POWDER VACCINE INJECTOR DEVELOPED, OWNED AND MANUFACTURED IN CANADA BY TRANSDERMAL, POWDER DRUG INJECTION TECHNOLOGY The patented “Nanojex System” painlessly delivers medicines through the skin, using a gas jet to accelerate powdered nanoparticles of drug or protein to supersonic speed wit
Slide 13: Industry Competitors: Current Valuation Comparisons
INDUSTRY COMPETITORS Current Valuation Comparisons PORTAL NUGEN MD CROSSJECT PHARMAJET INSTRUMENTS HQ: Toronto, Canada HQ: France HQ: Denver, U.S. HQ: Boston, U.S. (In development at MIT) Current Funding Round Annual Revenue Annual Revenue CAD$4.0M €2.1M/CAD$3.26M (H1' 2020) US$12M Previous R&D to c
Slide 14: Why Invest? Poised to Perform
WHY INVEST? PROJECTED REVENUES In CAD Injectors $35M 120k $31.2M 100K AGREEMENTS IN DEVELOPMENT $30M 100k In discussion with Specialty Pharma licensing deals POISED TO $25M 80k Direct-to-diabetic distribution strategy focused on clinics and hospitals PERFORM CUSTOMER PREDICTION Based on market poten
Slide 15: Notable Advisors
NOTABLE ADVISORS JOSEPH McCLENDON III VICENTE FOX DR. CAMILLO RICORDI DR. RONALD DENIS Author, Public speaker Former president of Mexico, Director, Diabetes Chief of Surgery and founder of the NGO Research Institute Sacré-Coeur Centro Fox University of Miami Hospital Montreal DR. RICHARD GALLO JIM B
Slide 16: Board of Directors & Management Team
BOARD OF DIRECTORS & MANAGEMENT TEAM MICHAEL G. WRIGHT VERONIQUE LABERGE NICKY CANTON DEREK LINDSAY DR. CLAUDE VEZEAU CHRIS BROWN CEO and President Chief Financial Officer Chief Operating Officer (COO), Head of Audit Committee Director of clinical Investor relations Design Engineer and MBA (Proposed
Slide 17: Corporate Structure and Use of Proceeds
CORPORATE STRUCTURE AND USE OF PROCEEDS Uses of Proceeds * in Canadian dollars Inolife Shares shares outstanding 62,993,870 Manufacturing Sales, Business General Product and Inventory Development Administration Development Options 461,666 $1,250,000 and Marketing $850,000 $500,000 Warrants 11,630,15
Slide 18: NuGen Medical Devices closing statement
NuGen Medical Devices are a catalyst to the commercialization of innovative needle-free solutions for the cure and care of the global community.
NuGen Medical Devices — Investor Presentation (July 2021) on 6ix